| abstract |
[PROBLEMS] To suppress the enhancement of transforming growth factor-β (TGF-β), metalloprotease tissue inhibitor (TIMP), collagen, etc., and to suppress the formation of extracellular matrix and / or the increase of fibrosis. Providing a pharmaceutical preparation capable of A pharmaceutical preparation comprising activated carbon, particularly spherical activated carbon as an active ingredient. [Effects] Examples of diseases showing the pathological condition of increased formation of extracellular matrix and / or increased fibrosis include, for example, heart diseases (eg, cardiac hypertrophy or myocardial infarction), liver diseases (eg, chronic hepatitis, liver fibrosis, Cirrhosis or liver cancer), effective for renal diseases (eg, chronic renal failure, interstitial nephritis, nephritis, or diabetic nephropathy), or vascular lesions (eg, arteriosclerotic lesions, diabetes, etc.) is there. [Selection figure] None |